Argus® II Retinal Stimulation System Feasibility Protocol

Retinitis Pigmentosa Clinical Trial

Official title:

Argus® II Retinal Stimulation System Feasibility Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00407602
• Other study ID #: CP-003-001
• Secondary ID: National Eye Ins
• Status: Completed
• Phase: N/A
• Start date: September 2006
• Est. completion date: December 31, 2019

Study information

• Verified date: January 2022
• Source: Second Sight Medical Products
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigational Phase of the Study:

The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa.

Post-Approval Phase of the Study:

To collect post-approval data in order to monitor the ongoing safety and reliability of the Argus II System

Description:

During the post-approval phase, subjects will undergo annual eye exams, assessments of medical status and adverse events, and measurement of stimulation thresholds. In addition, at the mutual agreement of the investigator and the subject, subjects will have the option of participating in psychophysical research which could occur as frequently as monthly. Functional tests at 10 years: photographic flash, square localization, direction of motion and grating visual acuity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A confirmed history of retinitis pigmentosa (all centers) or outer retinal degeneration (France, U.K., Switzerland, Mexico only) with remaining visual acuity of bare light perception (all centers) or 2.3 logMAR (France, U.K., Switzerland, Mexico only) or worse in both eyes.

• Functional ganglion cells and optic nerve as determined by a measurable electrically evoked response or documented light perception.

• A history of former useful form vision in the worse-seeing eye.

• Must be at least the following age at the time of enrollment: 25 (USA, Switzerland) or 18 (France, U.K., and Mexico) years old

• Must reside within 2 hours (USA, UK and Mexico) or 3 hours (France and Switzerland) distance (by ground transportation) of the investigational site.

• Must be willing and able to comply with the protocol testing and follow-up requirements.

Exclusion Criteria:

• Optic Nerve disease

• History of glaucoma

• Optic neuropathy or other confirmed damage to optic nerve or visual cortex damage

• Diseases or conditions that effect retinal function including but not limited to:

• Central retinal artery/vein occlusion (CRAO or CRVO)

• End-stage diabetic retinopathy

• Retinal detachment or history of retinal detachment

• Trauma

• Infectious or inflammatory retinal diseases

• Diseases or conditions that prevent adequate visualization of the retina including, but not limited to corneal degeneration that cannot be resolved before implant.

• Diseases or conditions of the anterior segment that prevent the ability to adequately perform the physical examination including but not limited to trauma or lid malpositions.

• Diseases of the ocular surface including but not limited to keratitis sicca.

• An ocular condition that predisposes the subject to eye rubbing.

• Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:

• Cognitive decline including diagnosed forms of dementia and/or progressive neurological disease

• Psychiatric Disease including diagnosed forms of depression

• Does not speak a principal language associated with the region

• Deafness or selective frequency hearing loss that prevents hearing device alarms and alerts.

• Pregnancy

• Subject has another active implantable device (e.g. cochlear implant), or any form of metallic implant in the head

• Conjunctival thinning which may predispose the subject to conjunctival erosion in the area where the implant will be installed extra-ocularly.

• Subject is participating in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study

• Any health concern that makes general anesthesia inadvisable.

• Subject has unrealistic expectations of the implant.

• Known allergy or contraindication to anticipated pre-operative, intra-operative or post-operative medications.

• Conditions likely to limit life to less than 1 year from the time of screening.

• Diseases or conditions that, in the judgement of the surgeon, impede the ability to implant the device or would prevent the system from functioning for the duration of the study (e.g. strabismus)

• Axial eye length <21.5 mm or >26.0 mm in the implanted eye as measured by ultrasound (US only)

Related Conditions & MeSH terms

• Retinitis
• Retinitis Pigmentosa

Intervention

Device:
• Implant of Argus II Retinal Prosthesis
epiretinal implantation of device

Locations

Country	Name	City	State
France	Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12	Paris
Mexico	Puerta de Hierro, Centro Medico, Centro de Retina	Zapopan	Jalisco
Switzerland	Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205	Geneva
United Kingdom	Moorfields Eye Hospital, Vitreoretinal Research Unit	London
United Kingdom	Manchester Royal Eye Hospital	Manchester
United States	Johns Hopkins, Wilmer Eye Institute	Baltimore	Maryland
United States	Retina Foundation of the Southwest	Dallas	Texas
United States	Doheny Eye Institute	Los Angeles	California
United States	Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute	New York	New York
United States	University of Pennsylvania, Scheie Eye Institute	Philadelphia	Pennsylvania
United States	Wills Eye Hospital	Philadelphia	Pennsylvania
United States	University of California San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Second Sight Medical Products	National Eye Institute (NEI)

Countries where clinical trial is conducted

United States,  France,  Mexico,  Switzerland,  United Kingdom, 

References & Publications (4)

Ahuja AK, Dorn JD, Caspi A, McMahon MJ, Dagnelie G, Dacruz L, Stanga P, Humayun MS, Greenberg RJ; Argus II Study Group. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. — View Citation

Barry MP, Dagnelie G; Argus II Study Group. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Invest Ophthalmol Vis Sci. 2012 Aug 1;53(9):5095-101. doi: 10.1167/iovs.12-9536. — View Citation

Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Eliott D, Filley E, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg RJ; Argus II Study Group. Interim results from the international trial of Second S — View Citation

Weiland JD, Faraji B, Greenberg RJ, Humayun MS, Shellock FG. Assessment of MRI issues for the Argus II retinal prosthesis. Magn Reson Imaging. 2012 Apr;30(3):382-9. doi: 10.1016/j.mri.2011.12.005. Epub 2012 Jan 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Acuity	Grating Visual Acuity is performed at Baseline and at various timepoints throughout the study. As of the 10 year final testing, the total number of subjects that were able to score on the logMAR scale are indicated below. The device has a scale from 1.6 to 2.9 logMAR. Maximum likelihood estimation of visual acuity is based on BEST-PEST algorithm.	10 years
Primary	Number of Participants With Adverse Events	Evaluate ocular adverse events reported for all subjects from day of implant through 10 years of study participation	10 years
Secondary	Massof Activity Inventory	The Massof Activity Inventory measures changes in ability to perform activities of daily living in terms of Goals and Tasks in logits (log-odds units). A logit scale is an equal interval linear scale that represents probability values in terms of real numbers. There is no minimum or maximum scale used in this testing. In this case, a Rasch distribution (using an Andrich rating model) was used to find the maximum likelihood of difficulty of achieving Goals and Tasks, represented in logits. The change in mean logit value between baseline and the 36Month visit for each subject are provided below along with the 95% confidence interval (CI) for the change. A positive change in the Goals or Tasks score which is greater than 0.2 (with a CI less than the mean logit value), is interpreted as a clinically significant increase in functional ability (better outcome).	3 years
Secondary	Quality of Life - Tasks for Daily Living	Quality of life is being measured using the VisQOL survey. This instrument, developed by researchers at the University of Melbourne, Australia, is a vision and quality of life-related utility measure intended to evaluate healthcare interventions for the visually impaired. The utility score is a preference-based measure of vision-related quality of life (Dimension 7 score (Health Dimension Score (1=Best, 0=Worst)). It measures subjective quality of life on a scale of 0 to 1, where 0 represents worst possible quality of life and 1 represents perfect quality of life.	3 years
Secondary	Orientation and Mobility	Argus II System for orientation and mobility, each subject completed two tests (walking to a high-contrast "door" on the wall and following a straight line on the floor) at various timepoints throughout the study. Accuracy (percent of trials where the subject successfully reached the target) was measured with the device system ON and system OFF. Average % success rates across the analysis population are provided for each modality and for each test at the 60 month time point.	5 years
Secondary	Visual Function	Square localization (SL) and Direction of Motion (DOM) testing performed at specific protocol intervals. SL tests ability of subjects to locate high-contrast square on black screen. DOM tests ability of subjects to determine the direction a white bar is moving over a black screen. Each test is performed with the system ON and then compared to performance with the system OFF. Number of subjects who performed significantly better with the system ON is indicated below.	10 years
Secondary	Stability of Implant - 5 Years Post Implant	Stability of electrode array on the retina. Qualitative review of imaging: retinal and array landmarks compared from all time points post implant.	5 years
Secondary	Device Reliability	Number of participants with functional devices 10 years post implant	10 years